Carmen Alcalá1, F Gascón2, F Pérez-Miralles3, S Gil-Perotín3, A Navarré2, I Boscá3, F Coret2, B Casanova3. 1. Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain. mc.alcalavicente@gmail.com. 2. Unit of Neuroimmunology, Department of Neurology, Hospital Clínico Universitario, Valencia, Spain. 3. Unit of Neuroimmunology, Department of Neurology, Hospital Universitari i Politècnic La Fe, 106 Avenue Fernando Abril Martorell, 46026, Valencia, Spain.
Abstract
INTRODUCTION: Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). OBJECTIVE: To investigate the effectiveness and safety of rituximab in MS. PATIENTS AND METHODS: Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS. RESULTS: A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. During treatment, the ARR was reduced an 88.4% (p < 0.001). A significant decrease of EDSS to 4.6 was observed (p = 0.01) after 1 year of treatment, which remained stable during the second year in both groups. There was no evidence of disease activity in 70% of total sample, 74.2% of RRMS, and 67% of the PMS patients. Infusion-related symptoms were the most prevalent side effect (18.8%) and most were mild. Three thrombotic events were detected. CONCLUSION: Rituximab could be an effective and safe treatment in aggressive RRMS. Some selected PMS patients could also benefit from this treatment.
INTRODUCTION: Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). OBJECTIVE: To investigate the effectiveness and safety of rituximab in MS. PATIENTS AND METHODS: Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS. RESULTS: A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. During treatment, the ARR was reduced an 88.4% (p < 0.001). A significant decrease of EDSS to 4.6 was observed (p = 0.01) after 1 year of treatment, which remained stable during the second year in both groups. There was no evidence of disease activity in 70% of total sample, 74.2% of RRMS, and 67% of the PMS patients. Infusion-related symptoms were the most prevalent side effect (18.8%) and most were mild. Three thrombotic events were detected. CONCLUSION: Rituximab could be an effective and safe treatment in aggressive RRMS. Some selected PMS patients could also benefit from this treatment.
Authors: S Martínez-Yélamos; A Martínez-Yélamos; G Martín Ozaeta; V Casado; O Carmona; Tx Arbizu Journal: Mult Scler Date: 2006-12 Impact factor: 6.312
Authors: Luisa M Villar; Bonaventura Casanova; Nadia Ouamara; Manuel Comabella; Farzaneh Jalili; David Leppert; Clara de Andrés; Guillermo Izquierdo; Rafael Arroyo; Timuçin Avşar; Sergey V Lapin; Trina Johnson; Xavier Montalbán; Oscar Fernández; Roberto Álvarez-Lafuente; Donna Masterman; María I García-Sánchez; Francisco Coret; Aksel Siva; Evgeniy Evdoshenko; José C Álvarez-Cermeño; Amit Bar-Or Journal: Ann Neurol Date: 2014-07-02 Impact factor: 10.422
Authors: Amit Bar-Or; Peter A J Calabresi; Douglas Arnold; Douglas Arnlod; Clyde Markowitz; Stuart Shafer; Lloyd H Kasper; Emmanuelle Waubant; Suzanne Gazda; Robert J Fox; Michael Panzara; Neena Sarkar; Sunil Agarwal; Craig H Smith Journal: Ann Neurol Date: 2008-03 Impact factor: 10.422
Authors: Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith Journal: N Engl J Med Date: 2008-02-14 Impact factor: 91.245
Authors: Yassir M Almatrafi; Mohammed A Babakkor; Muhammed Irfan; Ebaa T Samkari; Waleed M Alzahrani; Doaa K Mohorjy; Sarmad Zahoor; Muhammad T Farooq; Hafiz M Sajid Jehangir Journal: Neurosciences (Riyadh) Date: 2022-04 Impact factor: 0.735
Authors: Carmen Alcalá; F Gascón; Francisco Pérez-Miralles; J A Domínguez; S Gil-Perotín; B Casanova Journal: J Neurol Date: 2019-01-19 Impact factor: 6.682
Authors: Mena R Al-Ani; Tom K Raju; Mahmood Y Hachim; Ibrahim Y Hachim; Noha M Elemam; Maha Guimei; Riyad Bendardaf; Azzam A Maghazachi Journal: J Inflamm Res Date: 2020-03-10
Authors: Brandi L Vollmer; Kavita Nair; Stefan Sillau; John R Corboy; Timothy Vollmer; Enrique Alvarez Journal: Ann Clin Transl Neurol Date: 2020-08-06 Impact factor: 4.511